FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Ceftolozane and Tazobactam (Zerbaxa) Injection
Status: Currently in Shortage
»Date first posted: 01/04/2021
»Therapeutic Categories: Anti-Infective

Merck Sharp & Dohme Corp. (Reverified 09/17/2021)

Company Contact Information:

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Supplied in single-dose vials containing ceftolozane 1 g (equivalent to 1.147 g of ceftolozane sulfate) and tazobactam 0.5 g (equivalent to 0.537 g of tazobactam sodium) per vial. Vials are supplied in cartons containing 10 vials (NDC 67919-030-01) Unavailable, resupply is anticipated approximately December 2021 Requirements related to complying with good manufacturing practices

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English